In the last year, many Merck & Co., Inc. ( NYSE:MRK ) insiders sold a substantial stake in the company which may ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Various veterinary businesses and organizations recently announced new promotions and appointments. The following individuals ...

Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...

While the Dow Jones Industrial Average has reached all-time highs recently, one of its newest members, Merck, traded briefly Thursday morning at a 52-week low.

Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange ...

Dow has been struggling to grow for several quarters. Keytruda now makes up close to half of Merck's revenue. As you can see ...

In a report released yesterday, Mohit Bansal from Wells Fargo assigned a Hold rating on Merck & Company (MRK – Research Report), ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...

Burnout is a word we hear a lot, especially in the veterinary industry. But do we really know what it is, let alone how to beat it?